Pfizer Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 2,900 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Pfizer itself files Form 13F-HR as an institutional investment manager (CIK 0000078003), which is the source for all 17 holdings rows above. The Q2 2026 filing (period ended 30 June 2026, filed 13 August 2026) lists 20 information-table lines (three issuers reported over two lines each: Ginkgo Bioworks, NextCure and Pyxis Oncology) totaling $170,365,906 across 17 distinct issuers, matching the primary_doc.xml tableValueTotal. All are minority equity stakes in small and mid-cap public biotech companies, consistent with equity received or purchased alongside R&D collaboration and licensing deals rather than passive investing.
• Haleon: fully divested, zero remaining. Per the FY2025 10-K (Note 2C), Pfizer owned 32 percent of Haleon as of 31 December 2023, sold approximately 30 percent of that stake in March and October 2024 (leaving approximately 15 percent as of 31 December 2024), discontinued equity-method accounting in Q4 2024 and reclassified the residual stake to short-term investments at fair value, then sold the entire remaining portion in the first quarter of 2025 for $6.3 billion. The Q2 FY2026 10-Q confirms the Haleon sale proceeds line is nil in the six months to 28 June 2026 (versus $6,311 million in the comparable six months to 29 June 2025), consistent with a full exit before the current reporting period. No Haleon holding is recorded.
• ViiV Healthcare: also fully divested, zero remaining, as of the 28 June 2026 10-Q. Pfizer held approximately 11.7 percent of ViiV (a private company jointly owned with GSK, not itself SEC-registered). The equity-method carrying value of this stake had been zero on Pfizer's balance sheet since 2016 (cumulative equity-method losses and dividends reduced it to zero), even though the stake retained real economic value. In January 2026 Pfizer announced an agreement to sell its ViiV investment for $1.9 billion; the Q2 FY2026 10-Q confirms the sale completed 31 March 2026 for $1.875 billion cash, with a $1.870 billion net gain recognized in Q2 2026. No ViiV holding is recorded.
• Pfizer's balance sheet carries a combined 'Equity-method investments' line within Long-term investments ($241 million as of 28 June 2026, $235 million as of 31 December 2025) and a combined 'Private equity securities at cost' line described only as 'investments in the life sciences sector' ($718 million as of 28 June 2026, $696 million as of 31 December 2025). Neither the 10-Q nor the FY2025 10-K names the constituent investees of either bucket (Haleon and ViiV, the only two equity-method investees named anywhere in the filings, are both now at zero carrying value or fully divested, so they are not what makes up the $241 million balance). Per the research brief, a combined balance covering unnamed investees does not size any one of them; these two amounts are recorded here as balances only, not attributed to any named holding.
• No equity stake in BioNTech was found. Pfizer's filings reference BioNTech only in the context of the Comirnaty collaborative arrangement and related litigation, never as an equity investment.
• Register uses two different shares-outstanding denominators, matching what each source itself was closest to: the 30 June 2026 institutional 13F rows use 5,699,673,589 shares (the 10-Q cover page count as of 29 July 2026, the closest available count to those filings); the insider rows use 5,688,356,129 shares, the 2026 proxy's own stated count as of its 25 February 2026 record date, against beneficial ownership measured as of 31 January 2026.
• Vanguard disagreement, recorded rather than resolved. The Vanguard Group, Inc. (CIK 0000102909) last filed Form 13F-HR for the quarter ended 31 December 2025 (541,346,182 shares). For the quarters ended 31 March 2026 and 30 June 2026 it filed Form 13F-NT (notice, no holdings), so no more current Vanguard share count is available under this CIK. Pfizer's own 2026 proxy separately reports Vanguard at 506,479,807 shares (8.97 percent) as of an unstated date, sourced to a Schedule 13G/A filed 13 February 2024, which is older and lower than the 13F-HR figure used here.
• BlackRock disagreement, recorded rather than resolved. The register uses BlackRock, Inc.'s Form 13F-HR for the quarter ended 30 June 2026 (529,670,433 shares). Pfizer's 2026 proxy separately reports BlackRock at 434,748,255 shares (7.70 percent), sourced to a Schedule 13G/A filed 26 January 2024, which is two years stale next to the 13F.
• Pfizer's 2026 proxy also reports State Street Corporation at 287,875,814 shares (5.10 percent), sourced to a Schedule 13G/A filed 29 January 2024; this is lower than and older than the 307,090,897 shares used here from State Street's own 30 June 2026 Form 13F-HR.
• Pfizer has a single class of common stock, one vote per share, no dual-class structure. No director or executive officer holds a material voting block: the CEO's 378,551 shares are roughly 0.007 percent of the company, and all directors and executive officers as a group hold roughly 0.021 percent, consistent with the proxy's own statement that the group beneficially owns less than 1 percent.
• Market capitalization ($152.69 billion as of 14 August 2026) is from an aggregator (stockanalysis.com) and was not independently cross-derived from shares outstanding times a filed price within this task.
• Historical SC 13D/A filings under Pfizer's own CIK (most recently 3 October 2024) were checked and confirmed to be Pfizer's own reporting-person filings on Haleon (the subject company) from before the March 2025 full exit, not third-party activist filings against Pfizer.